Search

Your search keyword '"Rodbard H"' showing total 136 results

Search Constraints

Start Over You searched for: Author "Rodbard H" Remove constraint Author: "Rodbard H"
136 results on '"Rodbard H"'

Search Results

1. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

2. Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once‐weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1‐5, 7‐10 and SUSTAIN China

4. Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once‐weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1‐5, 7‐10 and SUSTAIN China.

14. Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2

15. Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2

24. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

25. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors

26. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

28. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

31. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

33. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

39. Wirksamkeit und Sicherheit von Liraglutid im Vergleich zu Placebo bei additiver Anwendung zu bestehenden Therapien mit Basalinsulinanaloga bei Patienten mit Typ 2 Diabetes (LIRA-ADD2BASAL): eine randomisierte, placebokontrollierte Studie

49. L’insuline faster asparten schéma basal-bolus permet d’obtenir une glycémie post-prandiale dans la cible

Catalog

Books, media, physical & digital resources